Canaccord analyst Edward Nash lowered the firm’s price target on Travere Therapeutics to $42 from $44 and keeps a Buy rating on the shares. The analyst said the target decrease is solely related to an increase in SG&A assumptions in 2023 and out years.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TVTX:
- Travere Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
- Travere Therapeutics announces $175M common stock offering
- Travere Therapeutics Announces Proposed Public Offering of Common Stock
- Travere Therapeutics reports Q4 EPS ($1.03), consensus ($1.07)
- Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
